ELiBio® is a Saas software that automatically extracts key quantitative markers from dedicated MRI acquisition.
Raw images from MRI scans are converted into parametric maps in which each pixel no longer corresponds to a gray scale value but to a quantitative parameter, a measurement of a tissue component.
Our patented technology uses biochemical shift and physical measurements derived from MRI (type and quantity of liver fat, iron content and magnetic susceptibility properties). These measurements are the key components related to the evaluation of MAFLD-MASH diseases, namely:
ELiBio solution is compatible with almost all MRI brands, models and magnetic fields available on the market and can be added anytime to MRI scanners already in use in Hospitals.
Completed study
(ROC AUC 95%CI: [0.79-1.0])
ELiBio® analysis report is automatically generated. It provides with key information to diagnose MASH presence and severity with:
Results are provided as average values for the whole liver as well as 3D distributions.
The MRI imaging procedure includes an optimized and dedicated MRI sequence. This breath-holding sequence lasts less than 20 seconds.
Once these images have been recovered form PACS, they are automatically prepared (Propriatory file formatting) for ELiBio analysis.
ELiBio core process uses patented technologies to compute quantitative biomarkers related to liver health. ELiBio generates 3D parametric mapping of these biomarkers and subsequently an analysis report.
The quantitative information produced allows the practitioner to: